These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37377931)

  • 1. Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model.
    Morales-Cano D; Izquierdo-García JL; Barreira B; Esquivel-Ruiz S; Callejo M; Pandolfi R; Villa-Valverde P; Rodríguez I; Cogolludo A; Ruiz-Cabello J; Perez-Vizcaino F; Moreno L
    Front Pharmacol; 2023; 14():1228923. PubMed ID: 37377931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model.
    Morales-Cano D; Izquierdo-García JL; Barreira B; Esquivel-Ruiz S; Callejo M; Pandolfi R; Villa-Valverde P; Rodríguez I; Cogolludo A; Ruiz-Cabello J; Perez-Vizcaino F; Moreno L
    Front Pharmacol; 2023; 14():1021535. PubMed ID: 37063275
    [No Abstract]   [Full Text] [Related]  

  • 3. Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis.
    Liu YY; Qu YY; Wang S; Luo CJ; Qiu HL; Li HT; Yuan P; Wang L; Li JL; Jiang R; Zhang R
    Front Pharmacol; 2023; 14():1155631. PubMed ID: 36891269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum: Identification of Hypoxia Induced Metabolism Associated Genes in Pulmonary Hypertension.
    He YY; Xie XM; Zhang HD; Ye J; Gencer S; van der Vorst EPC; Döring Y; Weber C; Pang XB; Jing ZC; Yan Y; Han ZY
    Front Pharmacol; 2021; 12():810178. PubMed ID: 34975506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capillary Degeneration and Right Ventricular Remodeling Due to Hypoxic Stress with Sugen5416.
    Woo E; Kato R; Imano H; Fujiwara Y; Ijiri Y; Okada Y; Yamaguchi T; Izumi Y; Yoshiyama M; Katsumata T; Hayashi T
    Curr Vasc Pharmacol; 2017; 15(6):589-598. PubMed ID: 28460626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrigendum for efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies).
    Pulm Circ; 2023 Apr; 13(2):e12250. PubMed ID: 37362561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal hemodynamic and histological progression in Sugen5416/hypoxia/normoxia-exposed pulmonary arterial hypertensive rats.
    Toba M; Alzoubi A; O'Neill KD; Gairhe S; Matsumoto Y; Oshima K; Abe K; Oka M; McMurtry IF
    Am J Physiol Heart Circ Physiol; 2014 Jan; 306(2):H243-50. PubMed ID: 24240870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic Reprogramming in the Heart and Lung in a Murine Model of Pulmonary Arterial Hypertension.
    Izquierdo-Garcia JL; Arias T; Rojas Y; Garcia-Ruiz V; Santos A; Martin-Puig S; Ruiz-Cabello J
    Front Cardiovasc Med; 2018; 5():110. PubMed ID: 30159317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching.
    Chamorro V; Morales-Cano D; Milara J; Barreira B; Moreno L; Callejo M; Mondejar-Parreño G; Esquivel-Ruiz S; Cortijo J; Cogolludo Á; Barberá JA; Perez-Vizcaino F
    PLoS One; 2018; 13(1):e0191239. PubMed ID: 29364918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Marra AM; Egenlauf B; Ehlken N; Fischer C; Eichstaedt C; Nagel C; Bossone E; Cittadini A; Halank M; Gall H; Olsson KM; Lange TJ; Grünig E
    Int J Cardiol; 2015 Sep; 195():19-26. PubMed ID: 26011408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Transition From Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study.
    Kuroda K; Akagi S; Nakamura K; Sarashina T; Ejiri K; Ito H
    Heart Lung Circ; 2020 Mar; 29(3):331-336. PubMed ID: 30773322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
    Yamamoto K; Tanabe N; Suda R; Sasaki A; Matsumura A; Ema R; Kasai H; Kato F; Sekine A; Nishimura R; Jujo T; Sugiura T; Shigeta A; Sakao S; Tatsumi K
    Respir Investig; 2017 Jul; 55(4):270-275. PubMed ID: 28705306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of riociguat in combination therapies for pulmonary arterial hypertension.
    Rahaghi FF; Trivieri MG; Sahay S
    Respir Med; 2023 May; 211():107196. PubMed ID: 36889521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corrigendum: The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-Word Prospective Study.
    Chen Y; Luo J; Chen J; Kotlyar E; Li Z; Chen W; Li J
    Front Pharmacol; 2022; 13():891907. PubMed ID: 35479317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riociguat: Clinical research and evolving role in therapy.
    Klinger JR; Chakinala MM; Langleben D; Rosenkranz S; Sitbon O
    Br J Clin Pharmacol; 2021 Jul; 87(7):2645-2662. PubMed ID: 33242341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
    Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
    Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling.
    Taran IN; Belevskaya AA; Saidova MA; Martynyuk TV; Chazova IE
    Lung; 2018 Dec; 196(6):745-753. PubMed ID: 30182153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction : Study protocol for a randomized controlled trial.
    Mascherbauer J; Grünig E; Halank M; Hohenforst-Schmidt W; Kammerlander AA; Pretsch I; Steringer-Mascherbauer R; Ulrich S; Lang IM; Wargenau M; Frey R; Bonderman D
    Wien Klin Wochenschr; 2016 Dec; 128(23-24):882-889. PubMed ID: 27590259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).
    Marra AM; Halank M; Benjamin N; Bossone E; Cittadini A; Eichstaedt CA; Egenlauf B; Harutyunova S; Fischer C; Gall H; Ghofrani HA; Hoeper MM; Lange TJ; Olsson KM; Klose H; Grünig E
    Respir Res; 2018 Dec; 19(1):258. PubMed ID: 30567595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riociguat therapy for pulmonary hypertension: a systematic review and meta-analysis.
    Wang L; Zhu L; Wu Y; Li Q; Liu H
    Ann Palliat Med; 2021 Oct; 10(10):11117-11128. PubMed ID: 34763472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.